Chronic myeloid leukemia

CML starts in a blood-forming stem cell and produces excessive myeloid cells, often including many mature white cells. Its defining BCR::ABL1 fusion usually results from a rearrangement between chromosomes 9 and 22, forming the Philadelphia chromosome.

Most people are diagnosed in chronic phase, when the disease is more responsive to treatment. Progression to blast phase means the accumulation of immature leukemia cells and a much more difficult illness. Classification systems differ in whether they retain a separate accelerated-phase category.

BCR::ABL1 makes an overactive tyrosine kinase, an enzyme that continually sends growth signals. The fusion is usually acquired in a blood-forming cell rather than inherited from a parent.

For most people there is no identifiable cause. High-dose radiation exposure is a recognized risk factor, but most patients have no such history. CML is not contagious. Its specific molecular driver makes it different from other chronic leukemias.

Some people have no symptoms and are diagnosed after an abnormal blood count. Others develop fatigue, night sweats, weight loss or fullness under the left ribs from an enlarged spleen.

In advanced disease, anemia, infections and bleeding can become more prominent as normal blood production fails. Blood counts alone do not show the whole response: molecular tests measure BCR::ABL1 during treatment.

Tyrosine kinase inhibitors (TKIs) target BCR::ABL1 and are the foundation of chronic-phase treatment. The initial choice takes account of disease risk, other health conditions, potential side effects and access. Molecular monitoring shows how well a medicine is suppressing the leukemia.

If the response is inadequate or side effects prevent treatment, the team checks adherence, interactions and possible resistance mutations before choosing another approach. Selected patients with a sustained deep molecular response may attempt treatment-free remission under a structured monitoring plan; medicines should not be stopped without that supervision.

Allogeneic transplantation is considered for resistance or intolerance to available TKIs and for advanced disease. Donor search can start before all drug options are exhausted when high-risk features or progression make a transplant likely. In blast phase, treatment commonly aims to regain disease control before transplant.

For many people, CML care centers on daily oral treatment and repeated blood tests rather than repeated inpatient chemotherapy. Side effects, medicine interactions and the practical effort of taking treatment consistently can still affect daily life.

Changing medicines does not have one universal meaning: it may reflect side effects, a laboratory response or resistance. People being assessed for transplant also need discussion of hospitalization, recovery support, fertility and longer-term follow-up.

A registry donor is not part of routine TKI treatment. A donor becomes relevant when allogeneic transplantation offers a reasonable balance of disease control and treatment risk.

A matched unrelated volunteer may be suitable, and a half-matched relative or mismatched unrelated donor can also be an option with an appropriate transplant approach. Lacking a fully matched donor does not automatically rule out transplantation. General donor recruitment supports patients who reach this pathway.

What is the exact diagnosis or subtype? What is the goal of each treatment option? If transplant is being considered, why does it fit this situation, which cells would be used and what are the alternatives?